An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if the commissioner determines the grounds for withdrawing Avastin's accelerated approval in breast cancer have been met, she could decide to retain the claim while Genentech conducts additional confirmatory trials, the hearing notice explains.